CN109200065A - The probiotics of autism-spectrum impaired patients symptom can be improved - Google Patents
The probiotics of autism-spectrum impaired patients symptom can be improved Download PDFInfo
- Publication number
- CN109200065A CN109200065A CN201811395345.6A CN201811395345A CN109200065A CN 109200065 A CN109200065 A CN 109200065A CN 201811395345 A CN201811395345 A CN 201811395345A CN 109200065 A CN109200065 A CN 109200065A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- autism
- spectrum
- probiotics
- impaired patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000006041 probiotic Substances 0.000 title claims abstract 16
- 235000018291 probiotics Nutrition 0.000 title claims abstract 16
- 206010003805 Autism Diseases 0.000 title claims abstract 13
- 208000020706 Autistic disease Diseases 0.000 title claims abstract 13
- 230000001771 impaired effect Effects 0.000 title claims abstract 13
- 238000001228 spectrum Methods 0.000 title claims abstract 13
- 208000024891 symptom Diseases 0.000 title claims abstract 10
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims abstract 5
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims abstract 5
- 244000199866 Lactobacillus casei Species 0.000 claims abstract 5
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract 5
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract 5
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract 5
- 241000194020 Streptococcus thermophilus Species 0.000 claims abstract 5
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims abstract 5
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract 5
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract 5
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract 4
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract 4
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract 4
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract 4
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract 4
- 239000000843 powder Substances 0.000 claims 5
- 230000000529 probiotic effect Effects 0.000 claims 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000011812 mixed powder Substances 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000003938 response to stress Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 claims 1
- 238000009777 vacuum freeze-drying Methods 0.000 claims 1
- 239000003643 water by type Substances 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 230000037213 diet Effects 0.000 abstract 1
- 235000005911 diet Nutrition 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 230000003860 sleep quality Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses probiotics technical fields, specific field is the probiotics that can improve autism-spectrum impaired patients symptom, and the probiotics for improving autism-spectrum impaired patients symptom is grouped as by the group of following mass ratio: the lactobacillus bulgaricus, lactobacillus plantarum, lactobacillus reuteri, streptococcus thermophilus, lactobacillus acidophilus and Lactobacillus casei mass ratio be 2~7:1~5:1~3:0.7~2.5:0.5~2:0.3~1.5.Pass through microorganism-intestines-brain axis mechanism of action, by scientific matching, it is prepared for that the probiotics of autism-spectrum impaired patients symptom can be improved, the core symptom of autism-spectrum impaired patients can be effectively improved, wherein the behavior improvement rate of autism-spectrum impaired patients is up to 80%, constipation improvement rate up to 80%, diarrhea improvement rate up to 40%, mood improvement rate up to 21%, diet improvement rate up to 16%, sleep quality improvement rate up to 12%.
Description
Technical field
The present invention relates to probiotics technical field, specific field is that can improve the prebiotic of autism-spectrum impaired patients symptom
Bacterium.
Background technique
Autism-spectrum obstacle (abbreviation ASD) refers to one group with more reasons, heterogeneous neurodevelopmental disorder, with mechanical
Behavior, language and social handicap are main feature, and severity of symptom is different, often merges several diseases, including anxiety
And gastrointestinal symptom etc., it is centainly contacted research shows that existing in terms of ASD and heredity, behavior and nervous system.Conventionally
ASD is closely related with heredity, but single-gene disorder and chromosome abnormality occupy the minority after all, at present about 9%~70% ASD patient
There is different degrees of gastrointestinal symptom, these symptoms include diarrhea, constipation, abdominal distension, abdominal pain etc..Therefore researcher thinks in ASD
There are the interactions of intestines brain to change during illness, and intestinal microecology imbalance may play the role of the cause of disease.Past 5 years, more than 4000
Document about intestinal flora is delivered on Pubmed, and wherein one of focus is microorganism-intestines-brain axis mechanism of action, raw
Microorganism living in enteron aisle contacts with enterocyte and immune system, and takes part in many neuropsychiatric diseases by contact
Disease and metabolic disorder.
At present to autism-spectrum obstacle in addition to rehabilitation maneuver (effect is limited), without other interference methods, according to micro- life
Object-intestines-brain axis therapy theory provides new thinking to improve ASD patient symptom, for this purpose, we have proposed can improve
The probiotics of autism-spectrum impaired patients symptom.
Summary of the invention
The purpose of the present invention is to provide the probiotics that can improve autism-spectrum impaired patients symptom, to solve above-mentioned back
The problem of being proposed in scape technology.
To achieve the above object, the invention provides the following technical scheme: autism-spectrum impaired patients symptom can be improved
Probiotics, composed of the following components:
Lactobacillus bulgaricus, lactobacillus plantarum, lactobacillus reuteri, streptococcus thermophilus, lactobacillus acidophilus, cheese cream bar
Bacterium.
Preferably, the lactobacillus bulgaricus, lactobacillus plantarum, lactobacillus reuteri, streptococcus thermophilus, acidophilus cream bar
The mass ratio of bacterium and Lactobacillus casei is 2~7:1~5:1~3:0.7~2.5:0.5~2:0.3~1.5.
Preferably, the autism-spectrum impaired patients pass through the marking of ABC, CARS and ATEC scale and are evaluated.
Preferably, the lactobacillus bulgaricus, lactobacillus plantarum, lactobacillus reuteri, streptococcus thermophilus, acidophilus cream bar
The viable count of bacterium and Lactobacillus casei is 10 × 108~30 × 108CFU/g。
Preferably, include the following steps:
1) by the lactobacillus bulgaricus of above-mentioned mass ratio, lactobacillus plantarum, lactobacillus reuteri, streptococcus thermophilus, thermophilic
Lactobacillus lactis and Lactobacillus casei sequentially add in food-grade batch mixer, are uniformly mixed, spare；
2) vacuum freeze-drying processing, freeze-drying are carried out to the probiotics mixed bacteria liquid that step 1) obtains using vacuum freeze drier
- 20 degrees Celsius of temperature, obtain mixed powder；
3) it is sieved to the probiotics Mixed Microbes powder that step 3) obtains, sieve partial size is 120 mesh, can be obtained probiotic powder.
Preferably, oral method is 40 DEG C or less warm boiled waters.
Preferably, dose is daily 360 × 108CFU~480 × 108CFU。
Preferably, for improving autism-spectrum impaired patients immunity, mitigation Systemic stress response, promoting digestion, net
Change enteron aisle, enhancing nutrition and improves sleep.
Compared with prior art, the beneficial effects of the present invention are: the prebiotic of autism-spectrum impaired patients symptom can be improved
Bacterium, the present invention are prepared for energy by scientific matching using probiotics as raw material, by microorganism-intestines-brain axis mechanism of action
The probiotics for improving autism-spectrum impaired patients symptom, can be effectively improved the core symptom of autism-spectrum impaired patients,
For the behavior improvement rate of middle autism-spectrum impaired patients up to 80%, constipation improvement rate is reachable up to 80%, diarrhea improvement rate
40%, mood improvement rate up to 21%, diet improvement rate up to 16%, sleep quality improvement rate up to 12%.
Probiotics provided by the invention generates antagonistic effect to pathogen, by changing intestinal environment and and enteric pathogenic bacteria
Competition mechanism is generated, so that the growth to enteric pathogenic bacteria generates inhibiting effect, reduces the infringement of enteric pathogenic bacteria；The present invention mentions
The probiotics of confession provides digestive ferment and autism-spectrum impaired patients is helped to digest and assimilate nutriment, promotes autism-spectrum obstacle
Patient's growth；Probiotics provided by the invention can make the general non-specific of body by stimulating enteron aisle pipe immune system cell
Immune function is transferred and is improved, to stimulate the foundation of body active immunity system, increases disease resistance ability；The present invention
The probiotics of offer can purify intestinal environment, reduce the production of ammonia and other corrupt substances, and bacterium in enteron aisle is hindered to generate
Amine neutralizes the toxicants such as escherichia coli endotoxin, and promotes enterogastric peristalsis, effectively reduces constipation diarrhea；It is provided by the invention
Probiotics can reduce the stress reaction of body, and adverse circumstances, microorganism invasion and drug therapy can make body generation stress be anti-
It answers, so that intestinal flora is kept balanced steady state by probiotic supplemented, so that stress reaction be made to be avoided and mitigate.
Specific embodiment
Below in conjunction with the embodiment of the present invention, technical solution of the present invention is clearly and completely described, it is clear that institute
The embodiment of description is only a part of the embodiment of the present invention, instead of all the embodiments.Based on the embodiments of the present invention,
Every other embodiment obtained by those of ordinary skill in the art without making creative efforts, belongs to this hair
The range of bright protection.
Embodiment 1: can improve the probiotics of autism-spectrum impaired patients symptom, be grouped as by the group of following mass ratio:
The lactobacillus bulgaricus, lactobacillus plantarum, lactobacillus reuteri, streptococcus thermophilus, lactobacillus acidophilus and dry
The mass ratio of Lactobacillus paracasei is 2:1:1:0.7:0.5:0.3.
Embodiment 2: can improve the probiotics of autism-spectrum impaired patients symptom, be grouped as by the group of following mass ratio:
The lactobacillus bulgaricus, lactobacillus plantarum, lactobacillus reuteri, streptococcus thermophilus, lactobacillus acidophilus and dry
The mass ratio of Lactobacillus paracasei is 3:2:1.5:0.9:0.6:0.5.
Embodiment 3: can improve the probiotics of autism-spectrum impaired patients symptom, be grouped as by the group of following mass ratio:
The lactobacillus bulgaricus, lactobacillus plantarum, lactobacillus reuteri, streptococcus thermophilus, lactobacillus acidophilus and dry
The mass ratio of Lactobacillus paracasei is 5:3:2:1.4:0.9:0.8.
Embodiment 4: can improve the probiotics of autism-spectrum impaired patients symptom, be grouped as by the group of following mass ratio:
The lactobacillus bulgaricus, lactobacillus plantarum, lactobacillus reuteri, streptococcus thermophilus, lactobacillus acidophilus and dry
The mass ratio of Lactobacillus paracasei is 6:4:2.5:2:1.3:1.1.
Embodiment 5: can improve the probiotics of autism-spectrum impaired patients symptom, be grouped as by the group of following mass ratio:
The lactobacillus bulgaricus, lactobacillus plantarum, lactobacillus reuteri, streptococcus thermophilus, lactobacillus acidophilus and dry
The mass ratio of Lactobacillus paracasei is 7:5:3:2.5:2:1.5.
The clinical effectiveness of the probiotics that can improve autism-spectrum impaired patients symptom of Examples 1 to 5 preparation is carried out
Verifying.
Test item: capacity, constipation, diarrhea, mood, diet and sleep matter are carried out to autism-spectrum impaired patients
The improvement of amount is tested.
Test method: autism-spectrum obstacle infant is evaluated by the marking of ABC, CARS and ATEC scale；It will be lonely
Only disease pedigree obstacle infant is divided into five groups, and it is corresponding take Examples 1 to 5 preparation can improve autism-spectrum impaired patients disease
The probiotics of shape；Autism-spectrum obstacle infant is commented again by the marking of ABC, CARS and ATEC scale after taking 30 days
It is fixed, feedback data is counted and records, assessment improves situation, and test result see the table below 1:
The result shows that autism-spectrum obstacle infant take the embodiment of the present invention 1~5 preparation can improve autism-spectrum
Have after the probiotics of impaired patients symptom and be obviously improved, wherein behavior improvement rate is up to 80%, constipation improvement rate up to 80%,
Diarrhea improvement rate is reachable up to 16%, sleep quality improvement rate up to 21%, diet improvement rate up to 40%, mood improvement rate
12%, by microorganism-intestines-brain axis mechanism of action, it is effectively improved the core symptom of autism-spectrum impaired patients.
It although an embodiment of the present invention has been shown and described, for the ordinary skill in the art, can be with
A variety of variations, modification, replacement can be carried out to these embodiments without departing from the principles and spirit of the present invention by understanding
And modification, the scope of the present invention is defined by the appended.
Claims (8)
1. the probiotics of autism-spectrum impaired patients symptom can be improved, it is characterised in that: composed of the following components:
Lactobacillus bulgaricus, lactobacillus plantarum, lactobacillus reuteri, streptococcus thermophilus, lactobacillus acidophilus, Lactobacillus casei.
2. the probiotics according to claim 1 that autism-spectrum impaired patients symptom can be improved, it is characterised in that: described
Lactobacillus bulgaricus, lactobacillus plantarum, lactobacillus reuteri, streptococcus thermophilus, lactobacillus acidophilus and Lactobacillus casei matter
Amount is than being 2~7:1~5:1~3:0.7~2.5:0.5~2:0.3~1.5.
3. the probiotics according to claim 1 that autism-spectrum impaired patients symptom can be improved, it is characterised in that: described
Autism-spectrum impaired patients pass through the marking of ABC, CARS and ATEC scale and are evaluated.
4. the probiotics according to claim 1 that autism-spectrum impaired patients symptom can be improved, it is characterised in that: described
The work of lactobacillus bulgaricus, lactobacillus plantarum, lactobacillus reuteri, streptococcus thermophilus, lactobacillus acidophilus and Lactobacillus casei
Bacterium number is 10 × 108~30 × 108CFU/g.
5. the probiotics according to claim 1 that autism-spectrum impaired patients symptom can be improved, it is characterised in that: including
Following steps:
1) by the lactobacillus bulgaricus of above-mentioned mass ratio, lactobacillus plantarum, lactobacillus reuteri, streptococcus thermophilus, acidophilus cream
Bacillus and Lactobacillus casei sequentially add in food-grade batch mixer, are uniformly mixed, spare；
2) vacuum freeze-drying processing, freeze-drying temperature are carried out to the probiotics mixed bacteria liquid that step 1) obtains using vacuum freeze drier
- 20 degrees Celsius of degree obtains mixed powder；
3) it is sieved to the probiotics Mixed Microbes powder that step 3) obtains, sieve partial size is 120 mesh, can be obtained probiotic powder.
6. probiotic powder according to claim 5, it is characterised in that: oral method is 40 DEG C or less warm boiled waters.
7. probiotic powder according to claim 5, it is characterised in that: dose is daily 360 × 108CFU~480 ×
108CFU。
8. the purposes of probiotic powder according to claim 5, it is characterised in that: for improving autism-spectrum impaired patients
Immunity mitigates Systemic stress response, promotes digestion, purification enteron aisle, enhancing nutrition and improve sleep.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811395345.6A CN109200065A (en) | 2018-11-22 | 2018-11-22 | The probiotics of autism-spectrum impaired patients symptom can be improved |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811395345.6A CN109200065A (en) | 2018-11-22 | 2018-11-22 | The probiotics of autism-spectrum impaired patients symptom can be improved |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109200065A true CN109200065A (en) | 2019-01-15 |
Family
ID=64993517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811395345.6A Withdrawn CN109200065A (en) | 2018-11-22 | 2018-11-22 | The probiotics of autism-spectrum impaired patients symptom can be improved |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109200065A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021157434A1 (en) * | 2020-02-05 | 2021-08-12 | 雪印メグミルク株式会社 | Sleep promoting composition, and food product, medicinal product, and animal feed containing said composition |
| WO2021157435A1 (en) * | 2020-02-05 | 2021-08-12 | 雪印メグミルク株式会社 | Sleep-promoting composition and foods, drugs, and feeds containing said composition |
| JP2021123562A (en) * | 2020-02-05 | 2021-08-30 | 雪印メグミルク株式会社 | Sleep-promoting compositions and foods, medicines, feeds containing the compositions |
| JP2021123561A (en) * | 2020-02-05 | 2021-08-30 | 雪印メグミルク株式会社 | Sleep-promoting compositions and foods, medicines, feeds containing the compositions |
| CN114990017A (en) * | 2022-06-09 | 2022-09-02 | 郑州大学第三附属医院(河南省妇幼保健院) | Probiotic composition for improving gastrointestinal function and sleep disorder and preparation method and application thereof |
| WO2022266469A1 (en) * | 2021-06-17 | 2022-12-22 | Biohm Health Llc | Probiotic compositions for alleviating gastrointestinal symptoms in subjects with a neurological disorder |
| US12233097B2 (en) | 2017-03-10 | 2025-02-25 | Biohm Health Inc. | Compositions and methods for promoting a healthy microbial flora in a mammal |
-
2018
- 2018-11-22 CN CN201811395345.6A patent/CN109200065A/en not_active Withdrawn
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12233097B2 (en) | 2017-03-10 | 2025-02-25 | Biohm Health Inc. | Compositions and methods for promoting a healthy microbial flora in a mammal |
| WO2021157434A1 (en) * | 2020-02-05 | 2021-08-12 | 雪印メグミルク株式会社 | Sleep promoting composition, and food product, medicinal product, and animal feed containing said composition |
| WO2021157435A1 (en) * | 2020-02-05 | 2021-08-12 | 雪印メグミルク株式会社 | Sleep-promoting composition and foods, drugs, and feeds containing said composition |
| JP2021123562A (en) * | 2020-02-05 | 2021-08-30 | 雪印メグミルク株式会社 | Sleep-promoting compositions and foods, medicines, feeds containing the compositions |
| JP2021123561A (en) * | 2020-02-05 | 2021-08-30 | 雪印メグミルク株式会社 | Sleep-promoting compositions and foods, medicines, feeds containing the compositions |
| JP2021123563A (en) * | 2020-02-05 | 2021-08-30 | 雪印メグミルク株式会社 | Sleep-promoting compositions and foods, medicines, feeds containing the compositions |
| JP2021123600A (en) * | 2020-02-05 | 2021-08-30 | 雪印メグミルク株式会社 | Sleep promoting composition, and food product, medicinal product and animal feed containing composition |
| CN115551365A (en) * | 2020-02-05 | 2022-12-30 | 雪印惠乳业株式会社 | Composition for promoting sleep, and food, drug and feed containing the same |
| WO2022266469A1 (en) * | 2021-06-17 | 2022-12-22 | Biohm Health Llc | Probiotic compositions for alleviating gastrointestinal symptoms in subjects with a neurological disorder |
| CN114990017A (en) * | 2022-06-09 | 2022-09-02 | 郑州大学第三附属医院(河南省妇幼保健院) | Probiotic composition for improving gastrointestinal function and sleep disorder and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109200065A (en) | The probiotics of autism-spectrum impaired patients symptom can be improved | |
| CN109288874A (en) | The probiotics of autism-spectrum impaired patients symptom can be improved | |
| Tellez et al. | Digestive physiology and the role of microorganisms | |
| CN112175864B (en) | Bifidobacterium animalis and breeding method and application thereof | |
| Toma et al. | Probiotics as functional food: microbiological and medical aspects | |
| CN102326678B (en) | Penta-composite probiotic powder preparation and preparation method thereof | |
| CN113855712B (en) | Composition capable of promoting defecation and application thereof | |
| Tomičić et al. | Beneficial properties of probiotic yeast Saccharomyces boulardii | |
| CN108570436A (en) | Lactobacillus plantarum ZJUF T17 and its application | |
| CN111548972A (en) | Lactobacillus plantarum with helicobacter pylori resistance function and application thereof | |
| CN109453207B (en) | Sodium selenylation alginate and chitosan selenylation coated probiotic double-layer microcapsule, preparation method and application thereof | |
| CN110150485A (en) | A biological feed additive for assisting the healthy growth of suckling piglets | |
| Roman et al. | Probiotics in digestive, emotional, and pain-related disorders | |
| CN113969253B (en) | A strain of Bifidobacterium lactis JYBR-390 with therapeutic effect on constipation and its application and products | |
| CN113122467A (en) | Lactobacillus paracasei and composition thereof | |
| WO2018018783A1 (en) | Method for manufacturing probiotics finishing agent | |
| CN117106628B (en) | Lactobacillus acidophilus LA15 with immunoregulation capability and application, product and method thereof | |
| CN116064313B (en) | Application of lactobacillus plantarum CCFM1281 in relieving exercise fatigue | |
| US10098916B2 (en) | Strains of the genus Lactobacillus and use thereof | |
| CN101851593B (en) | Lactobacillus plantarum strain LP28 and its use for alleviating allergic reactions | |
| MX2013005372A (en) | Non-replicating probiotic bacteria and prevention or treatment of infections to reduce absence from school or daycare. | |
| CN117384790B (en) | Pediococcus pentosaceus KS5 and application thereof in preparation of sleep-aiding drugs | |
| CN111616368A (en) | Composition with constipation relieving function and preparation method thereof | |
| KR20180056896A (en) | Microbial preparation(powder) for formula-fed babies produced with Lactobacillus gasseri J12P4 and Staphylococcus epidermidis J4P1 isolated from Korean breast milk | |
| CN110591950B (en) | A strain of Lactobacillus casei that can increase intestinal IL-22 expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190115 |
|
| WW01 | Invention patent application withdrawn after publication |